FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949684113> ?p ?o ?g. }

• W2949684113 abstract "C3 glomerulopathy (C3G) is an umbrella classification for severe renal diseases characterized by predominant staining for complement component C3 in the glomeruli. The disease is caused by a dysregulation of the alternative pathway (AP) of the complement system. In more than half of C3G patients C3 nephritic factors (C3NeFs) are found. These autoantibodies bind to the AP C3 convertase, prolonging its activity. C3NeFs can be dependent or independent of the complement regulator properdin for their convertase-stabilizing function. However, studies to determine the properdin-dependency of C3NeFs are rare and not part of routine patient workup. Until recently, only supportive treatments for C3G were available. Complement-directed therapies are now being investigated. We hypothesized that patients with properdin-dependent C3NeFs may benefit from properdin-inhibiting therapy to normalize convertase activity. Therefore, in this study we validated two methods to distinguish between properdin-dependent and properdin-independent C3NeFs. These methods are hemolytic assays for measuring convertase activity and stability in absence of properdin. The first assay assesses convertase stabilization by patient immunoglobulins in properdin-depleted serum. The second assay measures convertase stabilization directly in patient serum supplemented with the properdin-blocking agent Salp20. Blood samples from 13 C3NeF-positive C3G patients were tested. Three patients were found to have properdin-dependent C3NeFs, whereas the C3NeF activity of the other ten patients was independent of properdin. The convertase-stabilizing activity in the samples of the patients with properdin-dependent C3NeFs disappeared in absence of properdin. These data indicate that inhibition of properdin in patients with properdin-dependent C3NeFs can normalize convertase activity and could represent a novel therapy for normalizing AP hyperactivity. Our assays provide a tool for identifying C3G patients who may benefit from properdin-inhibiting therapy and can be incorporated into standard C3G laboratory investigations." @default.
• W2949684113 created "2019-06-27" @default.
• W2949684113 creator A5003038870 @default.
• W2949684113 creator A5004150357 @default.
• W2949684113 creator A5013799841 @default.
• W2949684113 creator A5013850585 @default.
• W2949684113 creator A5019777978 @default.
• W2949684113 creator A5023874285 @default.
• W2949684113 creator A5033389075 @default.
• W2949684113 creator A5041403060 @default.
• W2949684113 creator A5044473672 @default.
• W2949684113 creator A5046000826 @default.
• W2949684113 date "2019-06-17" @default.
• W2949684113 modified "2023-10-12" @default.
• W2949684113 title "Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy" @default.
• W2949684113 cites W129495913 @default.
• W2949684113 cites W1486365785 @default.
• W2949684113 cites W1490499121 @default.
• W2949684113 cites W1647249075 @default.
• W2949684113 cites W1963924977 @default.
• W2949684113 cites W1967188173 @default.
• W2949684113 cites W1967789154 @default.
• W2949684113 cites W1971659350 @default.
• W2949684113 cites W1977818941 @default.
• W2949684113 cites W2006870702 @default.
• W2949684113 cites W2014513484 @default.
• W2949684113 cites W2018301607 @default.
• W2949684113 cites W2038220053 @default.
• W2949684113 cites W2043478019 @default.
• W2949684113 cites W2049083092 @default.
• W2949684113 cites W2050217807 @default.
• W2949684113 cites W2054346519 @default.
• W2949684113 cites W2061729543 @default.
• W2949684113 cites W2063874378 @default.
• W2949684113 cites W2068258578 @default.
• W2949684113 cites W2072233870 @default.
• W2949684113 cites W2074855979 @default.
• W2949684113 cites W2077144266 @default.
• W2949684113 cites W2078519291 @default.
• W2949684113 cites W2081522308 @default.
• W2949684113 cites W2094275695 @default.
• W2949684113 cites W2094922401 @default.
• W2949684113 cites W2100824312 @default.
• W2949684113 cites W2103722562 @default.
• W2949684113 cites W2110998634 @default.
• W2949684113 cites W2135385588 @default.
• W2949684113 cites W2136648677 @default.
• W2949684113 cites W2136825683 @default.
• W2949684113 cites W2138581004 @default.
• W2949684113 cites W2151241196 @default.
• W2949684113 cites W2167821466 @default.
• W2949684113 cites W2194180979 @default.
• W2949684113 cites W2325522500 @default.
• W2949684113 cites W2343938697 @default.
• W2949684113 cites W2397512299 @default.
• W2949684113 cites W2469066751 @default.
• W2949684113 cites W2528498813 @default.
• W2949684113 cites W2565152113 @default.
• W2949684113 cites W2606241786 @default.
• W2949684113 cites W2734850302 @default.
• W2949684113 cites W2744480352 @default.
• W2949684113 cites W2761873674 @default.
• W2949684113 cites W2775288206 @default.
• W2949684113 cites W2781580267 @default.
• W2949684113 cites W2786188147 @default.
• W2949684113 cites W2795918852 @default.
• W2949684113 cites W2807577773 @default.
• W2949684113 cites W2808126109 @default.
• W2949684113 cites W2888224013 @default.
• W2949684113 cites W4211239325 @default.
• W2949684113 cites W4313311277 @default.
• W2949684113 cites W954655434 @default.
• W2949684113 doi "https://doi.org/10.3389/fimmu.2019.01350" @default.
• W2949684113 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6590259" @default.
• W2949684113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31263464" @default.
• W2949684113 hasPublicationYear "2019" @default.
• W2949684113 type Work @default.
• W2949684113 sameAs 2949684113 @default.
• W2949684113 citedByCount "12" @default.
• W2949684113 countsByYear W29496841132019 @default.
• W2949684113 countsByYear W29496841132020 @default.
• W2949684113 countsByYear W29496841132021 @default.
• W2949684113 countsByYear W29496841132022 @default.
• W2949684113 countsByYear W29496841132023 @default.
• W2949684113 crossrefType "journal-article" @default.
• W2949684113 hasAuthorship W2949684113A5003038870 @default.
• W2949684113 hasAuthorship W2949684113A5004150357 @default.
• W2949684113 hasAuthorship W2949684113A5013799841 @default.
• W2949684113 hasAuthorship W2949684113A5013850585 @default.
• W2949684113 hasAuthorship W2949684113A5019777978 @default.
• W2949684113 hasAuthorship W2949684113A5023874285 @default.
• W2949684113 hasAuthorship W2949684113A5033389075 @default.
• W2949684113 hasAuthorship W2949684113A5041403060 @default.
• W2949684113 hasAuthorship W2949684113A5044473672 @default.
• W2949684113 hasAuthorship W2949684113A5046000826 @default.
• W2949684113 hasBestOaLocation W29496841131 @default.
• W2949684113 hasConcept C111684460 @default.
• W2949684113 hasConcept C159654299 @default.
• W2949684113 hasConcept C189446657 @default.
• W2949684113 hasConcept C203014093 @default.

• next